MAC advances AIDS cause
This article was originally published in The Rose Sheet
Executive Summary
MAC AIDS Fund grants $2.5 mil. to Nurturing Orphans for AIDS for Humanity (NOAH) and UNICEF South Africa to fund testing and treatment for pregnant women and strengthen community infrastructure to care for children orphaned by AIDS, according to Nov. 24 announcement. The $2.5 mil. was raised $14 at a time through customer purchases of Viva Glam lipglosses and lipsticks across 16 countries, the sum total of which went to the MAC AIDS Fund. According to Ngashi Ngongo, UNICEF chief of health in South Africa, the partnership between UNICEF and MAC will help reduce the number of new HIV infections in children, keep mothers alive and lessen the number of orphans. Grant will also allow provincial governments to incorporate HIV testing into existing immunization programs. In the context of its study on cause-related marketing and its effect on consumer choice, communications agency Cone listed MAC's Viva Glam program among the "most sustainable, innovative and well-communicated programs that can be credited with shaping cause as we know it today" (1"The Rose Sheet" Oct. 13, 2008, p. 5)
You may also be interested in...
Firms Can Indeed Do Well By Doing Good, “Cause” Marketing Studies Show
Twenty-five years after American Express coined the term "cause-related marketing" in connection with its contributions to the Statue of Liberty restoration project, research indicates that corporate involvement in programs with societal benefits continues to influence consumer choice
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.